Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Pomalyst | Pomalidomide | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Iclusig | Ponatinib | Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete |